TGFB1 Antikörper

Produktnummer ABIN2665500

Produktdetails anti-TGFB1 Antikörper

Target: TGFB1 (Transforming Growth Factor, beta 1 (TGFB1))

Reaktivität: Säugetier

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TGFB1 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS)

Aufreinigung: The antibody was purified by antigen-affinity chromatography.

Klon: 21C11

Isotyp: IgG2a

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu TGFB1

Target: TGFB1 (Transforming Growth Factor, beta 1 (TGFB1))

Andere Bezeichnung: TGF-Beta1 (TGFB1 Produkte)

Synonyme: CED antikoerper, DPD1 antikoerper, LAP antikoerper, TGFB antikoerper, TGFbeta antikoerper, TGF-beta antikoerper, TGF-BETA-1 antikoerper, TGF-beta5 antikoerper, ced antikoerper, dpd1 antikoerper, lap antikoerper, tgf-beta antikoerper, tgfb antikoerper, tgfb5 antikoerper, tgfbeta antikoerper, TGF-beta1 antikoerper, TGFbeta1 antikoerper, Tgfb antikoerper, Tgfb-1 antikoerper, ai39657 antikoerper, tgfb1 antikoerper, wu:fb13a07 antikoerper, xx:ai39657 antikoerper, TGFB1 antikoerper, csd antikoerper, cdb1 antikoerper, cdg2 antikoerper, csd1 antikoerper, csd2 antikoerper, csd3 antikoerper, ebmd antikoerper, lcd1 antikoerper, bigh3 antikoerper, cdgg1 antikoerper, betaig-h3 antikoerper, TGFB4 antikoerper, transforming growth factor beta 1 antikoerper, transforming growth factor beta-1 antikoerper, transforming growth factor beta 1 L homeolog antikoerper, transforming growth factor, beta 1 antikoerper, transforming growth factor, beta 1a antikoerper, transforming growth factor beta induced L homeolog antikoerper, TGFB1 antikoerper, Tgfb1 antikoerper, tgfb1.L antikoerper, tgfb1a antikoerper, tgfbi.L antikoerper

Hintergrund: Transforming growth factor beta 1 (TGF-β1) is a member of the transforming growth factor beta superfamily of cytokines. The TGF-β1 precursor contains 390 amino acids with an N-terminal signal peptide of 29 amino acids required for secretion from a cell, a 249 amino acid pro-region (latency associated peptide or LAP), and a 112 amino acid C-terminal region that becomes the active TGF-β1 upon activation. Both LAP and TGF-β1 exist as homodimers in circulation, but the disulfide linked homodimers of LAP and TGF-β1 remain non-covalently associated, forming the small latent TGF-β complex (SLC, 100 kD). The large latent TGF-β complex (LLC, 235-260 kD) contains a third component, the latent TGF-β binding protein (LTBP), which is linked to LAP by a single disulfide bond. LTBP does not confer latency but is for efficient secretion of the complex to extracellular sites. Free active TGF-β1 can be released (activated) by many factors, including enzymes and low or high pH . TGF-β1 is nearly 100 % conserved across mammalian species. It has diverse biological functions in multiple cellular processes such as regulating proliferation and differentiation of various cell types. TGF-β1 is also an important immunoregulatory cytokine, which is involved in the maintenance of self-tolerance, Th17 differentiation, and T-cell homeostasis.

Pathways: EGFR Signaling Pathway, Dopaminergic Neurogenesis, Cellular Response to Molecule of Bacterial Origin, Glycosaminoglycan Metabolic Process, Regulation of Leukocyte Mediated Immunity, Regulation of Muscle Cell Differentiation, Positive Regulation of Immune Effector Process, Cell-Cell Junction Organization, Production of Molecular Mediator of Immune Response, Ribonucleoside Biosynthetic Process, Skeletal Muscle Fiber Development, Regulation of Carbohydrate Metabolic Process, Protein targeting to Nucleus, Autophagie, Cancer Immune Checkpoints